Ultherapy surpasses 1 million patient treatments

As of May 18th, 2017, based on data on file with Ulthera, Inc, a division of Merz Pharma, it is reported that over 1 million patient treatments have been performed worldwide and over 3,700 Ulthera® Systems are in use globally.

Merz warns against counterfeit Ulthera® Systems and fake Ultherapy® treatments

Merz Pharma Group, the parent company of Ulthera, Inc., is issuing an alert to consumers of potential illegal promotions of the non-invasive skin lifting Ultherapy® treatment. Merz has identified a number of companies selling fake versions of the Ulthera® System and physicians who purchase the fake device are falsely promoting Ultherapy® in their offices. Merz warns that these devices are not authentic Ulthera® Systems and in turn, the treatments being offered are not the authentic Ultherapy® treatment. Consumers who receive these fake treatments may not see results or may be susceptible to injury.   The Ulthera® System is the first and only ultrasound platform device to receive U.S. FDA clearance for lifting skin on the eyebrow, the neck, under the chin, as well as to improve the appearance of lines and wrinkles on the décolletage. The Ulthera® System is also FDA-cleared for the use of ultrasound imaging to help guide treatment. Copycat devices, which claim to offer similar benefits, do not have the same technology, clinical trials or years of studies that the Ulthera® System has to support their claims.   With over 1 million treatments performed worldwide, over 50 clinical studies and more than 40 published peer-reviewed papers, Ultherapy® has proven to be the leader in non-surgical skin lifting. The aesthetic lift indication differentiates Ultherapy® from every other energy device available in the market today. Many of the most esteemed aesthetic physicians in the world offer Ultherapy® and trust in the safety and satisfaction it provides their patients.

Ulthera, Inc. acquired by Merz Pharma; Ultherapy joins the Merz Aesthetics portfolio of solutions for addressing the signs of aging

Merz is a privately held pharmaceutical company based in Frankfurt, Germany with branches in various European countries as well as the U.S., Canada, Mexico, Brazil, and Asia-Pacific. The company is active in research, development, and distribution of innovative products in the areas of aesthetic medicine and neurologically induced movement disorders.


In July 2014 Merz acquired Ulthera, Inc., a medical device company pioneering aesthetic and medical applications using its therapeutic ultrasound platform technology. The Ulthera® System is the first and only energy-based device to receive U.S. FDA clearance for a non-invasive aesthetic lift indication. It is used in a face and neck procedure known as Ultherapy®, which is cleared to lift skin on the brow, neck and under the chin. The Ulthera® System is also indicated for use on the décolleté to improve the appearance of lines and wrinkles.


Merz Aesthetics offers a tailored and harmonized portfolio of products for minimally invasive treatments. With the dermal fillers Radiesse®, Belotero®, Glytone®, the botulinum neurotoxin Bocouture®, as well as the Neocutis line of anti-aging and post-procedure skincare products, the company is an important player in the global aesthetics market. The addition of Ulthera’s energy device technology in mid-2014 complements Merz’s current offerings and expands the specialty pharmaceutical company’s aesthetics portfolio. For the treatment of neurologically induced movement disorders, Merz developed Xeomin®, the first botulinum toxin that is free of complexing proteins.